Vanguard Capital Management’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$138M Buy
4,087,236
+448,555
+12% +$17.7M ﹤0.01% 1330
2026
Q2
$140M Buy
3,638,681
+18,631
+0.5% +$568K ﹤0.01% 1358
2026
Q1
$89.9M Buy
+3,620,050
New +$93.7M ﹤0.01% 1528

Other funds holding IMVT

Vanguard Capital Management's IMVT Position: Q3 2026 in Review

Vanguard Capital Management increased its Immunovant (IMVT) stake by 12% in Q3 2026, buying an estimated $17.7M and bringing the position to 4,087,236 shares worth $138M. The position accounts for ﹤0.01% of the portfolio, ranked #1330.

Vanguard Capital Management first reported a position in IMVT in Q1 2026 and has held it in 3 quarters since. The position peaked at $140M in Q2 2026. 231 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • Vanguard Capital Management held 4,087,236 shares of Immunovant worth $138M as of Q3 2026.
  • Vanguard Capital Management bought 448,555 Immunovant shares in Q3 2026, an estimated $17.7M.
  • Immunovant made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1330 holding.
  • Vanguard Capital Management first reported a position in Immunovant in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Immunovant position peaked at $140M in Q2 2026.
  • 231 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.